<DOC>
	<DOCNO>NCT00004028</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase I trial study effectiveness carmustine treat patient undergo surgery recurrent malignant glioma .</brief_summary>
	<brief_title>Carmustine Treating Patients With Recurrent Malignant Glioma</brief_title>
	<detailed_description>OBJECTIVES : - Determine safety polifeprosan 20 carmustine implant ( GLIADEL ) patient undergo surgery recurrent malignant glioma . OUTLINE : This dose escalation study . All patient undergo maximal tumor resection . At time surgery , group 6 patient receive 8 polifeprosan 20 wafer contain increase dos carmustine implant resection cavity . Patients intraoperative diagnosis glioblastoma multiforme anaplastic astrocytoma receive wafer implantation , remove study . Patients follow 3 , 6 , 12 month implantation . PROJECTED ACCRUAL : A total 52 patient accrue study .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Pathologically confirm recurrent malignant glioma surgery indicate Unilateral , supratentorial , solitary lesion least 1.0 cm diameter contrastenhanced CT MRI PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 60100 % Life expectancy : At least 8 week Hematopoietic : WBC least 3,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin , AST , ALT , alkaline phosphatase less 2.5 time normal Renal : Creatinine le 1.5 time normal BUN le 2.5 time normal Protein great 3 g/dL No gross hematuria Other : No hypersensitivity nitrosoureas Not pregnant Fertile patient must use effective contraception No concurrent life threaten disease PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent immunotherapy first 8 week study Chemotherapy : At least 4 week since chemotherapy ( 6 week since nitrosoureas ) No concurrent chemotherapy first 8 week study Endocrine therapy : Not specify Radiotherapy : Prior definitive externalbeam radiotherapy ( i.e. , least 5,000 cGy ) require No concurrent radiotherapy brachytherapy first 4 week study Surgery : Prior cytoreductive surgery supratentorial brain tumor require Biopsy alone sufficient Other : No concurrent investigational therapy first 8 week study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 1999</verification_date>
	<keyword>recurrent adult brain tumor</keyword>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult anaplastic astrocytoma</keyword>
	<keyword>adult anaplastic ependymoma</keyword>
	<keyword>adult anaplastic oligodendroglioma</keyword>
	<keyword>adult mixed glioma</keyword>
	<keyword>adult ependymoblastoma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
</DOC>